心血管

订阅

MedSci主页 / 所有栏目 / 心血管

吡格列酮可降冠心病合并糖尿病DES置入者支架内再狭窄率

2014-09-28 cath 整理 医学论坛网

吡格列酮冠心病合并糖尿病DES置入者支架内再狭窄率
关注

        钟雷、丛涛和苏德淳探讨了低剂量吡格列酮对冠心病合并糖尿病患者接受药物洗脱支架(DES)介入治疗后血管内膜增生和不良临床事件的影响。结果表明，吡格列酮可以减少冠心病合并糖尿病患者接受DES的支架内再狭窄率和不良心血管事件的概率。文章发表于第8期《临床心血管病杂志》。

        研究对象包括329例合并糖尿病的冠状动脉(冠脉)疾病患者,常规使用DES,被随机分配到服用吡格列酮组(161例,除应用其他降糖药物外,患者每日服用15mg吡格列酮)和对照组(168例,只接受基础降糖和安慰剂治疗)。术后平均随访时间1年。主要终点为支架内再狭窄(ISR),次要终点为全因死亡、再发心肌梗死、靶血管重建和支架内血栓形成。

        结果显示，随访1年,定量冠脉造影分析两组支架内再狭窄率差异有统计学意义(P<0.05)。吡格列酮组心血管不良事件发生率较对照组显著降低(6.08%∶12.08%,P<0.05)。吡格列酮组和对照组全因死亡(0∶1.34%)、再发心肌梗死(2.70%∶4.70%)、靶血管重建(2.03%∶4.03%)和支架内血栓形成(1.35%∶2.01%)的发生率均差异有统计学意义(均P<0.05)。单因素和多因素Cox回归分析基线数据发现,糖化血红蛋白(HbA1c)、是否使用吡格列酮和病变血管支数有预测再狭窄的作用,多因素分析证实只有后两项有独立预测作用。

        论文标题：低剂量吡格列酮对冠心病合并糖尿病患者冠状动脉支架内再狭窄的影响


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1985861, encodeId=1b80198586160, content=<a href='/topic/show?id=20605e09148' target=_blank style='color:#2F92EE;'>#支架内再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57091, encryptionId=20605e09148, topicName=支架内再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Jul 13 09:18:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447981, encodeId=9093144e9811a, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39186, encryptionId=dec73918624, topicName=吡格列酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28075374720, createdName=bioon5, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486181, encodeId=6e5814861811b, content=<a href='/topic/show?id=15b93065283' target=_blank style='color:#2F92EE;'>#再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30652, encryptionId=15b93065283, topicName=再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8f8090913, createdName=12498f1em10(暂无昵称), createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558491, encodeId=7a44155849144, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564500, encodeId=b9f2156450057, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=)]
    2015-07-13 ms3025846204744509

    #支架内再狭窄#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1985861, encodeId=1b80198586160, content=<a href='/topic/show?id=20605e09148' target=_blank style='color:#2F92EE;'>#支架内再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57091, encryptionId=20605e09148, topicName=支架内再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Jul 13 09:18:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447981, encodeId=9093144e9811a, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39186, encryptionId=dec73918624, topicName=吡格列酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28075374720, createdName=bioon5, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486181, encodeId=6e5814861811b, content=<a href='/topic/show?id=15b93065283' target=_blank style='color:#2F92EE;'>#再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30652, encryptionId=15b93065283, topicName=再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8f8090913, createdName=12498f1em10(暂无昵称), createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558491, encodeId=7a44155849144, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564500, encodeId=b9f2156450057, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=)]
    2014-09-30 bioon5

    #吡格列酮#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1985861, encodeId=1b80198586160, content=<a href='/topic/show?id=20605e09148' target=_blank style='color:#2F92EE;'>#支架内再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57091, encryptionId=20605e09148, topicName=支架内再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Jul 13 09:18:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447981, encodeId=9093144e9811a, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39186, encryptionId=dec73918624, topicName=吡格列酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28075374720, createdName=bioon5, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486181, encodeId=6e5814861811b, content=<a href='/topic/show?id=15b93065283' target=_blank style='color:#2F92EE;'>#再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30652, encryptionId=15b93065283, topicName=再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8f8090913, createdName=12498f1em10(暂无昵称), createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558491, encodeId=7a44155849144, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564500, encodeId=b9f2156450057, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=)]
    2014-09-30 12498f1em10(暂无昵称)

    #再狭窄#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1985861, encodeId=1b80198586160, content=<a href='/topic/show?id=20605e09148' target=_blank style='color:#2F92EE;'>#支架内再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57091, encryptionId=20605e09148, topicName=支架内再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Jul 13 09:18:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447981, encodeId=9093144e9811a, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39186, encryptionId=dec73918624, topicName=吡格列酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28075374720, createdName=bioon5, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486181, encodeId=6e5814861811b, content=<a href='/topic/show?id=15b93065283' target=_blank style='color:#2F92EE;'>#再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30652, encryptionId=15b93065283, topicName=再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8f8090913, createdName=12498f1em10(暂无昵称), createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558491, encodeId=7a44155849144, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564500, encodeId=b9f2156450057, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=)]
    2014-09-30 fusion

    #DES#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1985861, encodeId=1b80198586160, content=<a href='/topic/show?id=20605e09148' target=_blank style='color:#2F92EE;'>#支架内再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57091, encryptionId=20605e09148, topicName=支架内再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Jul 13 09:18:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447981, encodeId=9093144e9811a, content=<a href='/topic/show?id=dec73918624' target=_blank style='color:#2F92EE;'>#吡格列酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39186, encryptionId=dec73918624, topicName=吡格列酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28075374720, createdName=bioon5, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486181, encodeId=6e5814861811b, content=<a href='/topic/show?id=15b93065283' target=_blank style='color:#2F92EE;'>#再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30652, encryptionId=15b93065283, topicName=再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8f8090913, createdName=12498f1em10(暂无昵称), createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558491, encodeId=7a44155849144, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564500, encodeId=b9f2156450057, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=)]
    2014-09-30 fusion

    #DES#

    0

相关资讯

FDA批准吡格列酮的仿制药上市

美国食品药品管理局(FDA)8月17日宣布，已批准2型糖尿病口服治疗药物吡格列酮的首个仿制药上市。 吡格列酮是一种噻唑烷二酮类药物(TZD)，于1999年通过审批，用于在饮食和运动治疗的基础上改善2型糖尿病患者的血糖控制，由武田制药公司美国分部销售，商品名为艾可拓。用法为每日1次，不受进食时间影响。 本次获准的仿制药是由Mylan制药公司生产的，通过审批的为15 mg、30 mg和45 m

含吡格列酮和艾塞那肽的三联疗法优于传统逐步递增治疗

　　胰岛素抵抗及进行性β细胞衰竭是2型糖尿病进展的主要原因。ADA和欧洲糖尿病研究学会（EASD）推荐，在避免发生低血糖的前提下，应尽可能将患者HbA1c降至正常水平。然而，之前并无研究探讨其最佳治疗方案。　　美国田纳西大学圣安东尼奥健康医学中心阿卜杜勒-加尼（Abdul-Ghani）等认为，对新诊断2型糖尿病患者，目前推荐的以二甲双胍序贯递加磺脲类及基础胰岛素治疗仅着眼于降低血糖，

Nature综述：多囊卵巢综合症诊治概述

引言 多囊性卵巢综合症（PCOS）是女性最常见的内分泌疾病。据报道，育龄妇女PCOS发病率为6%-20%，发病率取决于所用的诊断标准。典型PCOS临床表现常一起出现，症状主要与雄激素过多（如多毛症、粉刺或脱发）和无排卵（月经稀发、不规律、闭经和/或不孕）有关。 此外，PCOS可增加2型糖尿病（T2DM）发病风险，并与心血管疾病风险升高有关。超重/肥胖可加重PCOS生殖代谢异常。

中国上市的吡格列酮产品列表

4月8日，美国一陪审团判罚武田制药支付60亿美元赔偿金，原告律师称该公司隐瞒了与其糖尿病药物吡格列酮（Actos）相关的癌症风险。 该巨额罚金判决在路易斯安那州拉斐特座无虚席的法庭上宣布时，现场鸦雀无声，原告律师Mark Lanier这样说。礼来是武田的共同被告，该公司被命令支付30亿美元惩罚性赔偿。 武田制药是日本最大的制药公司，该公司称不同意此次判决结果，将通过上市后试验数据监测及

降糖药吡格列酮或面临限制使用

　　据了解，8月4日，美国食品和药物管理局(FDA)官网称，吡格列酮使用一年多以上可能增加罹患膀胱癌的风险。而据道琼斯通讯社消息，法国与德国已于7月上旬暂停了这款药物的临床使用。在中国，国家食品药品监督管理局(SFDA)还没有做出相关通知。 　　TZD类糖尿病药物或将“全军覆没” 　　吡格列酮，是很多用于治疗2型糖尿病的药物的重要成分。在罗格列酮(以文迪雅为代表)被严格限制使用之后，吡格列酮本

郭艺芳：由艾可拓（吡格列酮）的遭遇所想到的

       编者按：2014年4月8日，美国路易斯安那州的地区法院判罚武田制药美国有限公司支付60亿美元、共同被告礼来赔付30亿美元赔偿金，原告律师称该公司隐瞒了与其糖尿病药物吡格列酮(艾可拓)相关的癌症风险。吡格列酮在临床应用非常广泛，国内还有近20种其他厂家的相关药品。此消息一出，舆论哗然。河北省人民医院郭艺芳教授对此也发